Joon Lee
Stock Analyst at Truist Securities
(4.65)
# 185
Out of 4,854 analysts
119
Total ratings
55.14%
Success rate
38.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterates: Buy | $95 → $75 | $27.83 | +169.49% | 8 | Apr 28, 2025 | |
| ARVN Arvinas | Maintains: Buy | $65 → $21 | $7.53 | +178.88% | 6 | Apr 9, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $76 → $150 | $69.60 | +115.52% | 8 | Mar 31, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $90 → $50 | $8.09 | +518.05% | 4 | Mar 4, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $175 → $85 | $44.59 | +90.63% | 5 | Mar 3, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $190 → $200 | $111.91 | +78.72% | 5 | Feb 19, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $100 → $120 | $41.86 | +186.67% | 5 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $460 → $520 | $450.50 | +15.43% | 3 | Feb 11, 2025 | |
| LRMR Larimar Therapeutics | Initiates: Buy | $18 | $2.68 | +571.64% | 1 | Jan 29, 2025 | |
| ARGX argenx SE | Reiterates: Buy | $660 → $700 | $585.97 | +19.46% | 12 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $44 → $57 | $84.34 | -32.42% | 6 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.54 | +252.42% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $36 | $7.22 | +398.61% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $25.87 | +39.16% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.91 | +318.85% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $13 → $8 | $6.85 | +16.79% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $17 | $13.98 | +21.60% | 7 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $90 | $56.65 | +58.87% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $2.83 | +1,313.43% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $111.13 | +79.97% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.84 | +76.06% | 7 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.54 | +408.47% | 1 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $280 | $3.18 | +8,705.03% | 1 | Oct 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $27 → $34 | $23.70 | +43.46% | 1 | Mar 16, 2021 |
Viking Therapeutics
Apr 28, 2025
Reiterates: Buy
Price Target: $95 → $75
Current: $27.83
Upside: +169.49%
Arvinas
Apr 9, 2025
Maintains: Buy
Price Target: $65 → $21
Current: $7.53
Upside: +178.88%
Corcept Therapeutics
Mar 31, 2025
Maintains: Buy
Price Target: $76 → $150
Current: $69.60
Upside: +115.52%
Intellia Therapeutics
Mar 4, 2025
Maintains: Buy
Price Target: $90 → $50
Current: $8.09
Upside: +518.05%
Praxis Precision Medicines
Mar 3, 2025
Maintains: Buy
Price Target: $175 → $85
Current: $44.59
Upside: +90.63%
Axsome Therapeutics
Feb 19, 2025
Maintains: Buy
Price Target: $190 → $200
Current: $111.91
Upside: +78.72%
CRISPR Therapeutics AG
Feb 12, 2025
Maintains: Buy
Price Target: $100 → $120
Current: $41.86
Upside: +186.67%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Buy
Price Target: $460 → $520
Current: $450.50
Upside: +15.43%
Larimar Therapeutics
Jan 29, 2025
Initiates: Buy
Price Target: $18
Current: $2.68
Upside: +571.64%
argenx SE
Jan 14, 2025
Reiterates: Buy
Price Target: $660 → $700
Current: $585.97
Upside: +19.46%
Jan 8, 2025
Reiterates: Buy
Price Target: $44 → $57
Current: $84.34
Upside: -32.42%
Jan 8, 2025
Initiates: Buy
Price Target: $16
Current: $4.54
Upside: +252.42%
Nov 12, 2024
Maintains: Buy
Price Target: $17 → $36
Current: $7.22
Upside: +398.61%
Nov 11, 2024
Maintains: Buy
Price Target: $30 → $36
Current: $25.87
Upside: +39.16%
Nov 5, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.91
Upside: +318.85%
Oct 30, 2024
Maintains: Hold
Price Target: $13 → $8
Current: $6.85
Upside: +16.79%
Oct 22, 2024
Maintains: Buy
Price Target: $12 → $17
Current: $13.98
Upside: +21.60%
Sep 17, 2024
Maintains: Buy
Price Target: $118 → $90
Current: $56.65
Upside: +58.87%
Aug 14, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $2.83
Upside: +1,313.43%
Mar 20, 2024
Reiterates: Buy
Price Target: $200
Current: $111.13
Upside: +79.97%
Sep 20, 2023
Maintains: Buy
Price Target: $6 → $5
Current: $2.84
Upside: +76.06%
May 10, 2023
Initiates: Buy
Price Target: $18
Current: $3.54
Upside: +408.47%
Oct 20, 2021
Initiates: Buy
Price Target: $280
Current: $3.18
Upside: +8,705.03%
Mar 16, 2021
Upgrades: Buy
Price Target: $27 → $34
Current: $23.70
Upside: +43.46%